Definition

Mechanism of Action

  1. Antibody-dependent cellular cytotoxicity (ADCC) – recruits NK cells/macrophages to kill B-cells.
  2. Complement-dependent cytotoxicity (CDC) – activates complement cascade → cell lysis.
  3. Direct apoptosis induction – binding to CD20 triggers programmed cell death in some cells.

Key Anti-CD20 Agents

Drug Type Route Indications Notes / Toxicity
Rituximab Chimeric (mouse/human) IgG1 IV NHL, CLL, autoimmune diseases Infusion reactions, HBV reactivation, cytopenias
Obinutuzumab Humanized, glycoengineered IgG1 IV CLL, FL Higher ADCC than rituximab; IRR common, cytopenias
Ofatumumab Fully human IgG1 IV CLL, MS (off-label in oncology limited) Infusion reactions, less immunogenic than rituximab; cytopenias

Administration & Dosing Highlights

  • IV infusion (most common), sometimes subcutaneous (ofatumumab).
  • Premedication recommended: acetaminophen + antihistamine ± corticosteroid.
  • Infusion rate: start slow, escalate gradually; reduce or stop if IRR occurs.

Key Toxicities

  • Infusion-related reactions (IRR) – fever, chills, hypotension, rash; most occur during first infusion.
  • Infections – increased risk due to B-cell depletion; HBV reactivation is a serious risk → screen before therapy.
  • Cytopeniasneutropenia, thrombocytopenia.
  • Rare: tumor lysis syndrome, cardiac events (rare).

Monitoring

  • CBC before each cycle; monitor for neutropenia and infections.
  • Hepatitis B screening before therapy.
  • Vital signs during infusion.
  • Immunoglobulin levels if long-term therapy (risk of hypogammaglobulinemia).

Summary

 

Anti-CD20 antibodies (rituximab, obinutuzumab, ofatumumab) are cornerstone therapies in B-cell malignancies. They deplete B-cells via ADCC, CDC, and apoptosis. Main concerns are infusion reactions, infection risk (especially HBV reactivation), and cytopenias. Proper premedication and monitoring are essential.

Synonyms
Anti-CD20
Links